Menu
GOVPH
  • Home
  • HTA Governance
    • Universal Health Care Act
    • Administrative Order on HTA
    • Philippine HTA Process Guide
    • Philippine HTA Methods Guide
    • Philippine HTA Code of Conduct
    • HTA Philippines Social Values Guide
  • About Us
    • Mission/Vision
    • Health Technology Assessment Council (HTAC)
    • Health Technology Assessment Division (HTAD)
    • HTA Philippines Annual Report
      • 2021 HTA Annual Report
      • 2020 HTA Annual Report
      • 2019 HTA Annual Report
    • Road to HTA Institutionalization
    • External Partners
  • Assessments
  • Issuances
  • Evidence Briefs
  • FAQs
  • Get Involved with Us
    • Careers
    • Contact Us
    • Call for Nomination
    • Topic Nomination
  • AUXILIARY MENU
  • GOVPH
  • Home
  • HTA Governance
    • Universal Health Care Act
    • Administrative Order on HTA
    • Philippine HTA Process Guide
    • Philippine HTA Methods Guide
    • Philippine HTA Code of Conduct
    • HTA Philippines Social Values Guide
  • About Us
    • Mission/Vision
    • Health Technology Assessment Council (HTAC)
    • Health Technology Assessment Division (HTAD)
    • HTA Philippines Annual Report
      • 2021 HTA Annual Report
      • 2020 HTA Annual Report
      • 2019 HTA Annual Report
    • Road to HTA Institutionalization
    • External Partners
  • Assessments
  • Issuances
  • Evidence Briefs
  • FAQs
  • Get Involved with Us
    • Careers
    • Contact Us
    • Call for Nomination
    • Topic Nomination

Preliminary Recommendation

HTAC PRELIMINARY RECOMMENDATION FOR GOVERNMENT FINANCING OF ZOLEDRONIC ACID for Individuals with Malignancy-Related Bone Disease

Revised HTAC preliminary recommendation on the inclusion of Insulin Detemir and the non-inclusion of Insulin glargine in the PNF

preliminary recommendation for the inclusion of insulin glargine and insulin detemir for type 1 and type 2 diabetes mellitus in the PNF

preliminary recommendation for the non-inclusion of eribulin in the treatment of soft tissue sarcoma in the PNF

preliminary recommendation for the inclusion of Potassium Citrate 1620 mg (15 mEq) tablet in the PNF.